research use only
Cat.No.S1379
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Hydroxylase Inhibitors | Ro 61-8048 Meldonium 4-Chloro-DL-phenylalanine (R)-Nepicastat HCl Nepicastat (SYN-117) HCl H-Tyr(3-I)-OH 2-Thiouracil |
|
In vitro |
DMSO
: 60 mg/mL
(199.7 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 300.44 | Formula | C20H28O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 4759-48-2 | Download SDF | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
hydroxylase
|
|---|---|
| In vitro |
Isotretinoin (13-cis retinoic acid) directly interferes with the development of cranial neural crest cells. This compound selectively affects neural crest cells by decreasing their cell-substratum adhesion.
|
| In vivo |
Isotretinoin (13-cis retinoic acid) (500 ng/mL) and its main metabolite in the human, 4-oxo-isotretinoin, induce malformations similar to those seen in vivo. It impairs explicit memory in Stage 2, but retention tests one month after exposure ended, indicated recovery from this explicit memory impairment and evidence of enhanced implicit memory in the 10 mg and 15 mg ISO rats. This compound slows the recovery of rod signaling after exposure to an intense bleaching light, and that rhodopsin regeneration is markedly slowed. It is also found to protect rat photoreceptors from light-induced damage. Isotretinoin blocks the formation of A2E biochemically and the accumulation of lipofuscin pigments by electron microscopy. It also blocks the slower, age-dependent accumulation of lipofuscin in wild-type mice.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06225570 | Not yet recruiting | Acne Vulgaris |
Medical University of South Carolina |
January 2025 | Early Phase 1 |
| NCT05316675 | Not yet recruiting | Acne Vulgaris |
Assiut University |
December 2022 | Phase 4 |
| NCT03939364 | Withdrawn | Leukoplakia Oral |
Skyline Biosciences |
January 2022 | Phase 1 |
| NCT05218486 | Active not recruiting | Acne Vulgaris |
Alshimaa Abbas Mohamed Ebrahim|Aswan University |
August 1 2021 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.